If you want to turn Coronavirus into a more lethal weapon, you need to make sure its entry into Human cells is enhanced.

The Covid19 virus Spike protein comes as a trimer of intertwined proteins that lock onto membrane bound ACE2 enzyme that is expressed in many cell types throughout the body.

1

Furin is a protease enzyme we have performing many useful functions in our bodies.

2

As shown in this figure 3 review by German scientists from early 2019, a number of pathogenic viruses exploit our Furin to assist with cell entry, including Mumps, Measles, Avian Influenza, Ebola, Dengue Fever, Hepatitis, Herpes, HIV, and HPV. This has led research into drugs that might inhibit Furin as therapies against the pathogens.

4

2002

In 2002 a patent was lodged for insertion of a Furin Cleavage Site sequence in a plasmid comprising a chicken β in Glucagon Like Peptide-1 (GLP-1) cDNA (pβGLP1).

The sequence SEQ ID NO: 5(CGTCAACGTCGT) codes for a Furin Cleavage Site(FCS).

North Carolina researchers Kristopher Curtis, Boyd Yount and Ralph Baric filed a patent “Methods for producing recombinant Coronavirus”.

2003

In 2003 researchers in Utrecht, Netherlands, investigating recombinant Murine Coronavirus found that Furin, or a Furin-like protease was necessary to allow cleavage of the Spike Protein. Inhibition of the protease did not affect virus-cell fusion, but did prevent cell-cell fusion.

It was discovered that Furin helps to unravel the Covid19 Spike so that it can more easily invade cells.

The figure above shows the shows clever research measuring the levels of both ACE2 and Furin in oral tissues.

Furin also occurs in Covid19 target organs: lung, heart, nose, rectum, colon, intestine, and ileum.

This explains why it is useful to take swabs or spittle samples for PCR or RAT tesing for Covid19 because the virus loves this environment more than the nasopharyngeal passages and uses the mouth as its primary launchpad to infect other hosts.

Let us look at the deliberate insertion of a Furin cleavage site done by those with an interest in weaponizing Coronaviruses year by year.

2005

In 2005 (published in 2006), scientists at the The University of Montana, Missoula, working on Gain of Fuction, inserted a Furin cleavage site into SARSCov.

That virus differed from Murine Hepatitis Virus (MHV), and in the Avian Group 3 viruses, where the S glycoprotein precursor is cleaved, by furin-like cellular proteases. They were disappointed that the modification apparently did not increase infectivity although it increases cell-cell fusion.

Earlier scientists at School of Veterinary Medicine, Louisiana State University, Baton Rouge were also manipulating SARSCov.

2006

Spanish researchers engineered a full-length infectious cDNA clone and a functional replicon of the severe acute respiratory syndrome coronavirus (SARS-CoV) Urbani strain as bacterial artificial chromosomes (BACs).

2008

In 2008 the Furin cleavage site was introduced by Japanese researchers who also discovered that cleavage of the Spike protein helped it defeat natural cell defences.

The authors of this paper played crucial roles in further genetic modifications of Coronavirus via international collaboration.

2013

Ralph Baric of University of North Carolina at Chapel Hill, announced development of a cassette-based infectious cDNA clone of MERS-CoV and verified that it functions similarly to the wild-type isolate in terms of replication, protein and RNA expression, and spike attachment protein processing. The virus replicates preferentially in differentiated primary lung cells.

A strain of deadly MERS-CoV, which does not infect Mice or Hamsters, was illegally imported to the University of Iowa in 2013 from Spain.

They then created infectible Humanized Mice, via Adenoviral vectors expressing the human host-cell receptor Dipeptidyl Peptidase 4. They then made a mRNA vaccine using Venezuelan Equine Encephalitis Replicon particles expressing MERS-CoV spike protein.

2014

In 2014 researchers at Cornell University, Ithaca, New York announced that host cell entry of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) proceeds in a two-step, furin-mediated activation of the Spike Protein.

BioNTech founders published a review

of mRNA Gene Therapies from the discovery of mRNA in 1961, through the pioneering work of Robert W Malone et al.

who used cationic lipid to insert GMO mRNA into the cells of numerous species, and pointing to their future vision of mRNA LNP applications, using this timeline depiction.

2015

Pfizer BioNTech depends on LNP delivery of the mRNA, using technology developed by Acuitas Therapeutics of Vancouver Canada and University of Pennsylvania.

They got the LNPs into genetically modified, Humanized mice, by different routes, including intravenous, intraperitoneal, subcutaneous, intramuscular, intradermal, and intratracheal.

2016

85% kill rate of BALB/c mice was achieved in 2016 with SARS-CoV infection in Iowa US by researchers collaborating with Germany and China.

Photo kindly supplied by Aaron Logan ex Wikipedia. But that depends on your Mouse Strain. Young mice from many strains (e.g., C57BL/6, 129) support SARS-CoV replication in the lungs but develop Mild or Subclinical disease, mimicking Mild Human disease.

2019

In August 2019 the Bill and Melinda Gates Foundation signed an agreement with BioNTech

which included Clause 3(e)

“Pandemic Response. If during the conduct of the HIV Project Statement of Work or TB Project Statement of Work there is a need for an emergency response to a pandemic of an infectious disease that has not already been partnered with a third party [***], the Foundation can request the Company to accept a grant-funded project in response to such pandemic, and the Company may elect to accept such funding at its sole discretion, which may include the development of a drug, vaccine or diagnostic, and the Company will negotiate in good faith with the Foundation to reach agreement on such pandemic response project.”

In October 2019 Ralph Baric and coworkers at Chapel Hill North Carolina, University of Texas Medical Branch, Galveston, Texas, Columbia University, New York, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, announced their work on Bat Coronavirus demonstrating the importance of proteases in infection, using exogenous Trypsin.

2020

In January 2020 the full genomic sequence of the Wuhan Covid19 was known and shared with virus labs around the world.

On 21 January 2020, Chinese scientists announced that the Wuhan Covid19 contained a Furin cleavage site.

In June 2020 scientists in China and UK published cryo electron microscopy structure determination for both furin-cleaved and uncleaved SARS-CoV-2 Spike and the closely related Bat virus, RaTG13. They also found about 1,000-fold tighter binding of SARS-CoV-2 to human receptor ACE2.

A document obtained by FOI from TGA points out that Wild Type, i.e. not transgenic GMO Mice, are unsuitable for testing Covid19 jabs because they are not particularly bothered by the virus. Adjunct Prof John Skerritt does not want you to see some important information on that topic. Elsewhere in the same document, it states Rhesus Macaques also suffer only mild symptoms when infected.

TGA accidentally exposes Redaction

Notice the blacked out sentence in the FOI page above?

I have discovered what is hidden:

“Antigen-specific enzyme linked immunosorbent assays (ELISA) and virus neutralisation assays using pseudovirion (mouse study and rat repeat dose toxicity study) or wild-type SARS-CoV-2 virus (monkey study and rat repeat dose and reproductive toxicity study) were used to characterise the humoral response.”

Why didn’t TGA want us to see that?

Hamsters, ferrets, minks, cats, and nonhuman primates all have been found to be susceptible to Covid19 and there is evidence of interspecies transfer.

In late 2020, researchers in Spain used Humanized mice which express ACE2 to because wild type mice are not a good test animal.

The Forgotten BioNTech Phase 1 Trial in Germany

BioNTech and Pfizer launched a coordinated program to compare four RNA-based Covid-19 pandemic vaccine candidates in umbrella-type clinical studies conducted in Germany (BNT162-01)

and the United States (C4591001).

The program was designed to support the selection of a single vaccine candidate and dose level for a pivotal international safety and efficacy trial.

The German arm of the trial showed that the free floating BNT162b1 spike caused increased C-Reactive Protein and massive collapse of Lympocytes.

The US Phase 1 Trial that gets all the Publicity

On the basis of initial clinical-trial results in Germany, two lipid nanoparticle–formulated, nucleoside-modified RNA (modRNA) vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were evaluated in the phase 1 portion of the trial in the United States.

It is vital to understand that Pfizer new that free floating Synthetic Spike from Jab version BNT162b1 was judged far too toxic, so Pfizer BioNTech used the so-called Membrane-Anchored BNT162b2 for subsequent Phase 2/3 trial and then mass rollout.

China Phase 1 Trial to determine effects on Asian Races

Pfizer BioNTech were interested to see if there are variations by Race in reaction to their jabs, especially Asian people, a prime target for making extra profits.

So a little known subset of the Phase 1 trial using the BNT162b1 free floating mRNA, rejected by the German and US arms, was carried on in China. It too showed collapse of Lymphocytes.

In this graph, close inspection shows that the CCP has a more protective standard for FEVER, compared to the US FDA, classifying more jabbee victim fever as Severe.

The China arm of the Phase 1 trial found that people aged 65-85 years had sustained Higher Systolic and Diastolic Blood Pressure for 15 Days after their jab than Placebo recipients.

NovaVax mutates the Furin Cleavage site June 2020

It is interesting that a paper submitted by NovaVax in June 2020 was not published in final form until January 2021. NovaVax announced that they had mutated the Furin Cleavage site to be protease resistant to generate the full-length BV2365 variant.

2021

Professor Yoshiharu Matsuura of Japan and coworkers devised a PCR-based, bacterium-free method to generate SARS-CoV-2 infectious clones.

The same group from Japan demonstrated the phenomenon of Antibody Enhancement.

They screened a series of anti-spike monoclonal antibodies from coronavirus disease 2019 (COVID-19) patients and found that some of antibodies against the N-terminal domain (NTD) induced the open conformation of RBD and thus enhanced the binding capacity of the spike protein to ACE2 and infectivity of SARS-CoV-2. Mutational analysis revealed that all of the infectivity-enhancing antibodies recognized a specific site on the NTD.

2022

In October 2022, Boston University researchers created a stir when they announced they created a new, more lethal recombinant strain of Covid19, despite the fact that Gain of Function research was presumed not to be ongoing in the US.

This was only made possible by importation of Plasmid as a “kind gift” from Yoshiharu Matsuura of Japan and collaboration with Biological Weapons experts in Germany.

Pfizer BioNTech used Synthetic Life for Tests

Synthetic Life made in US laboratories, recombinant SARS-CoV-2 was designed which replicates as efficiently as the original clinical isolate. In order to screen Human fluid samples to detect antiviral inhibitors a mNeonGreen SARS-CoV-2 virus was made at Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas.

This technology arose from years of collaboration in Gain of Function research in Wuhan and a number of laboratories in US.

Using stock of SARS-CoV-2 strain 2019-nCoV/USA_WA1/2020 derived from the first Wuhan patient diagnosed in the US. The virus isolate was originally provided by Dr. Natalie Thornburg from the Centers for Disease Control and Prevention in Atlanta Georgia, then Galveston grew more virus in African Green Monkey Kidney epithelial cells but genetically engineered a fully replicating Clone so they could make the colour reaction test. Three of the authors, Xuping Xie, Vineet D Menachery and Pei-Yong Shi filed a provisional patent on the reverse genetic system of SARS-CoV-2.

Galveston commercialized their test for antibodies to Covid19 which takes 3 days using the following materials, including live GMO virus culture.

Conclusion

Pfizer BioNTech had all the connections with Coronavirus manipulators in many countries who developed the technology necessary to conduct clinical trials of synthetic Covid19 Spike Protein made by mRNA designed to take over Human cells by defeating natural immunity.

More will be added to the timeline as it comes to hand.

This article was republished from the author’s Substack